If you have lived with a PCOS diagnosis, or suspected you might have it for years without getting straight answers, something important happened on May 12, 2026. The condition you have heard called Polycystic Ovary Syndrome for decades has been officially renamed. It is now called Polyendocrine Metabolic Ovarian Syndrome, or PMOS.
This is not a rebrand. It is not a minor administrative update. For many women, it is the formal acknowledgment of what they have known in their bodies for a long time: this condition was never just about their ovaries.
The new name was announced through a landmark publication in The Lancet and presented at the European Congress of Endocrinology. It was led by Professor Helena Teede and a global team of researchers and clinicians representing more than 50 patient and professional organizations. The process involved more than 22,000 survey responses and multiple international workshops. This was years of collaborative work aimed at getting the terminology right, finally.
The transition is underway now, but full implementation is expected with the 2028 International Guideline update. In the meantime, clinicians are still using established diagnostic criteria, and care is continuing. What is changing is the framework that surrounds it.
For women in their 30s, 40s, and 50s navigating perimenopause, metabolic shifts, weight changes, fatigue, and long-term health planning, this name change has real meaning. Here is what you need to know.
Quick Answer: PCOS Is Now Called PMOS
What changed? The name Polycystic Ovary Syndrome has been officially renamed Polyendocrine Metabolic Ovarian Syndrome. The announcement was made on May 12, 2026, published in The Lancet, and presented at the European Congress of Endocrinology.
What does PMOS stand for? Polyendocrine Metabolic Ovarian Syndrome. The new name reflects that multiple hormone systems are involved (polyendocrine), that metabolic dysfunction such as insulin resistance is a core feature (metabolic), and that ovarian function still matters (ovarian), while also acknowledging the wide variation in how the condition presents (syndrome).
Why did the name change? The old name was misleading. “Polycystic” implied that ovarian cysts were central or required for diagnosis, but the structures seen on ultrasound are typically follicles, not abnormal cysts. Many women with the condition do not have polycystic-appearing ovaries. The previous name over-focused on reproductive anatomy and contributed to missed diagnoses, stigma, and incomplete care across a woman’s lifespan.
Does this change diagnosis or treatment immediately? Not yet in a sweeping way. Diagnostic criteria remain based on the 2023 International Evidence-Based Guideline for the Assessment and Management of PCOS while the terminology transition takes place. Full implementation of updated criteria is expected with the 2028 international guideline update. The condition is not new. The name is new.
Why the Name “PCOS” Was Always Incomplete
The term Polycystic Ovary Syndrome dates back decades. When it was coined, the prevailing understanding of the condition was narrower, and clinical tools were more limited. At the time, the visible ultrasound finding of multiple follicles on the ovaries was a defining feature, and naming the condition after that finding made a certain kind of sense.
The problem is that science moved forward, and the name did not.
Researchers and clinicians have understood for years that the ovaries are not the origin of this condition. They are one of the sites where hormonal dysregulation becomes visible, but they are not the cause. The roots of PMOS run through insulin signaling, adrenal function, hypothalamic-pituitary regulation, androgen pathways, and metabolic physiology.
The name “polycystic” created specific clinical problems. It suggested that ovarian cysts were required for the diagnosis, when in reality the structures seen on ultrasound are often small antral follicles in greater-than-typical numbers, not abnormal cysts. Some women with the condition have no polycystic ovarian appearance on ultrasound at all. And some women who do have that appearance on imaging do not have the syndrome.
This ambiguity led to real harm. Women with clear metabolic and hormonal features of the condition were told they did not have PCOS because their ovaries looked “normal.” Women with polycystic-appearing ovaries were told they had PCOS when they did not meet the full criteria. Across the board, the old name skewed clinical attention toward ovaries and fertility, leaving the rest of the picture under-addressed.
The name also carried stigma. For many women, hearing that they had a condition with “cysts” in the name, often delivered alongside discussions of infertility and weight, felt like a pronouncement rather than a doorway to care.
The 2023 International Evidence-Based Guideline for the Assessment and Management of PCOS, developed through a global collaboration anchored by the Monash Centre for Health Research and Implementation, was already pushing the field toward a broader view of the condition. The name change to PMOS formalizes what that guideline made clinically clear: this is a whole-body condition with lifelong implications.
What PMOS Means: Breaking Down the New Name
Polyendocrine: More Than One Hormone System
The prefix “poly” means many. “Endocrine” refers to hormone-producing glands and systems. Put them together, and polyendocrine means that more than one hormone system is involved.
That is precisely what we see in PMOS. The condition involves dysregulation across multiple axes:
- Ovarian hormone production, including estrogen, progesterone, and androgens
- Adrenal androgen output, including DHEA-S and androstenedione
- Pituitary signaling, including elevated LH relative to FSH in some presentations
- Hypothalamic regulation of the reproductive axis
- Insulin and glucose signaling, which affects androgen availability and ovarian function
- Thyroid function, which is often a co-existing variable that must be assessed and ruled out or addressed
No single hormone system drives PMOS in isolation. It is a condition of interacting systems. That is why addressing only one pathway, say cycle regulation with oral contraceptives, often leaves a woman feeling only partially helped.
Metabolic: The Missing Piece in the Old Name
The word “metabolic” in the new name is arguably the most important addition.
Insulin resistance is present in an estimated 65 to 70 percent of women with PMOS, including women with lean body types. This is not a peripheral feature. For many women, it is a central driver of symptoms, from excess androgen production to ovulatory dysfunction to weight-loss resistance to cravings and energy instability.
When insulin is chronically elevated and cells become resistant to its signals, several things happen. The ovaries produce more androgens. Sex hormone-binding globulin (SHBG) decreases, which means more free testosterone circulates in the bloodstream. The hypothalamic-pituitary-ovarian axis becomes dysregulated. Inflammation rises. Fat storage patterns shift toward the abdomen and visceral compartments. Risk for type 2 diabetes, dyslipidemia, non-alcoholic fatty liver disease, and cardiovascular disease increases over time.
None of this was captured in the word “ovary.” And yet for most women with PMOS, the metabolic dimension is what drives the most significant long-term health risk.
Acknowledging “metabolic” in the name is an invitation for clinicians to assess it, track it, and treat it, not just note it.
Ovarian: Still Important, But Not the Whole Story
The ovarian component is retained in the new name intentionally. Ovulatory function, reproductive hormones, follicular development, androgen production from ovarian theca cells, fertility, and cycle regularity all remain important features of PMOS and central to the clinical picture for many women.
Retaining “ovarian” is also important for clarity. This is not the same as metabolic syndrome broadly, or adrenal hyperplasia, or hypothyroidism. The ovarian dimension is real and meaningful. It is simply not the only dimension, and the new name reflects that balance.
Syndrome: Why Symptoms Look Different From Woman to Woman
A syndrome is a collection of features that tend to occur together, but not every feature is present in every person. This is one of the most important things to understand about PMOS.
Two women can both meet the diagnostic criteria and have almost no overlap in their symptom experience. One woman may have significant androgen-related symptoms like hirsutism and acne with relatively preserved cycle regularity. Another may have no visible androgen symptoms but significant metabolic dysfunction, irregular cycles, and fatigue. A third may have struggled with fertility, weight, and insulin resistance since adolescence, while a fourth receives her first diagnostic consideration in her 40s when perimenopause amplifies what was previously subclinical.
PMOS is heterogeneous. That is a clinical fact, not a qualification. It means that evaluation and care must be individualized, not protocol-stamped.
Why PMOS Matters for Women Over 35
PMOS does not stop being relevant when fertility is no longer a priority. For many women, the condition becomes more clinically visible, not less, in perimenopause and menopause. This is an area where women with PMOS have historically been underserved.
During the reproductive years, estrogen provides some degree of metabolic protection. It supports insulin sensitivity, lipid balance, and vascular tone. As estrogen levels fluctuate and decline in perimenopause, that protection begins to erode. For women with underlying PMOS-related insulin resistance, this shift can be significant.
Here is what the intersection of PMOS and midlife physiology often looks like:
Cycle changes become harder to interpret. Irregular cycles in perimenopause are expected, but women with PMOS already have baseline ovulatory irregularity. When the two overlap, symptoms can become more pronounced and harder to attribute clearly, which means diagnosis can be delayed even further, or dismissed as “just perimenopause.”
Androgen symptoms may persist or shift. Estrogen decline can alter the relative balance between estrogen and androgens. Some women notice an increase in facial hair, acne, or scalp thinning in midlife that they attribute to aging, when PMOS physiology is playing a role.
Metabolic risk increases. Women with a history of PCOS or PMOS already have elevated baseline risk for insulin resistance, dyslipidemia, impaired fasting glucose, and cardiovascular disease. Estrogen loss accelerates some of these same processes. The overlap is clinically significant and deserves proactive attention.
Visceral fat increases. The shift in fat distribution that accompanies menopause, from peripheral to visceral, overlaps with patterns seen in PMOS-related metabolic dysfunction. This is not a cosmetic concern. Visceral adiposity is an independent driver of inflammation, insulin resistance, and cardiovascular risk.
Sleep disruption compounds everything. Hot flashes, night sweats, and hormonal fluctuations in perimenopause disrupt sleep architecture. Sleep deprivation worsens insulin resistance, cortisol dysregulation, appetite signaling, and cardiometabolic markers. Women with PMOS are also at elevated risk for sleep apnea, which further layers the problem.
Mental health deserves attention. Women with PMOS have higher rates of anxiety, depression, and eating disorder history. Perimenopause has its own neurological and psychological dimensions. The intersection requires clinical attention, not dismissal.
The core message is this: if you were diagnosed with PCOS in your 20s or 30s, or suspected it but never received a clear workup, the transition into midlife is not the time to assume the condition has resolved or become irrelevant. It is the time to look at the full picture more carefully than ever.
Common Signs and Symptoms of PMOS
PMOS does not present identically in every woman. The following symptoms are associated with the condition, but not every woman will experience every feature. A clinician should evaluate what is present, what is absent, and what other causes need to be excluded.
Hormonal and Reproductive
- Irregular, infrequent, or absent menstrual cycles
- Ovulatory dysfunction or anovulation
- Infertility or difficulty conceiving
- Heavy or unpredictable bleeding patterns in some presentations
- Elevated androgen levels on labs or clinical assessment
Androgen-Related Symptoms
- Acne, particularly on the jaw, chin, or chest in adult women
- Excess facial or body hair growth (hirsutism)
- Scalp hair thinning or androgenic alopecia
- Oily skin
Metabolic and Weight-Related
- Weight gain, particularly around the abdomen
- Difficulty losing weight despite consistent effort
- Strong cravings, particularly for carbohydrates and sugar
- Blood sugar swings or energy crashes after meals
- Fatigue, especially postprandial or persistent
Cardiovascular and Inflammatory
- Elevated triglycerides or unfavorable lipid patterns
- Elevated blood pressure in some women
- Elevated inflammatory markers
- Fatty liver findings on imaging
Sleep and Nervous System
- Poor sleep quality or difficulty staying asleep
- Increased risk for sleep apnea
- Elevated cortisol responses to stress
Mood and Mental Health
- Anxiety
- Depression
- Disordered eating patterns or difficult relationship with food
- Body image distress
Skin and Other
- Skin darkening in skin folds, called acanthosis nigricans, associated with insulin resistance
- Skin tags
Again, no woman needs every feature on this list to have PMOS. The condition is diagnosed on specific clinical and biochemical criteria, not on a symptom checklist alone.
Diagnosis: What Has Changed and What Has Not
The terminology has changed. The diagnostic criteria are still based on the 2023 International Evidence-Based Guideline for the Assessment and Management of PCOS while the transition to PMOS language takes place. Full implementation of any updated diagnostic framework is expected with the 2028 guideline update.
Current diagnosis generally involves first excluding other conditions that can produce similar features, such as thyroid dysfunction, hyperprolactinemia, congenital adrenal hyperplasia, and Cushing syndrome. Once other causes have been excluded, the diagnosis is typically based on identifying at least two of the following three features:
Clinical or biochemical hyperandrogenism. This may mean symptoms like hirsutism, acne, or scalp hair thinning, confirmed or supported by elevated androgen levels on lab testing.
Ovulatory dysfunction. This typically means irregular, infrequent, or absent menstrual cycles, although lab or other confirmation may be needed in women with cycles that appear regular but may not be ovulatory.
Polycystic ovarian morphology on ultrasound, or elevated AMH. In adults, anti-Müllerian hormone (AMH) is now recognized as an alternative to ultrasound for assessing ovarian morphology. In adolescents, neither ultrasound nor AMH is recommended for diagnostic purposes due to poor specificity in that age group.
An important nuance: when both irregular menstrual cycles and hyperandrogenism are present, ultrasound or AMH may not be required to complete the diagnostic picture.
This article does not provide personal diagnostic guidance. If you are uncertain about your status, work with a clinician who is familiar with the current international guidelines and who will look at your full clinical and laboratory picture.
The Metabolic Side of PMOS: Why Insulin Resistance Matters
Insulin is a hormone produced by the pancreas. Its primary job is to signal cells to take up glucose from the bloodstream so it can be used for energy or stored for later.
Insulin resistance means that cells have become less responsive to that signal. The pancreas compensates by producing more insulin, which keeps blood glucose in a relatively normal range, at least initially. But chronically elevated insulin has consequences throughout the body.
In PMOS, elevated insulin:
- Stimulates the ovaries to produce more androgens, particularly testosterone
- Suppresses production of sex hormone-binding globulin (SHBG) in the liver, which means more free androgens circulate
- Disrupts pituitary signaling, contributing to ovulatory dysfunction
- Promotes visceral fat storage
- Drives chronic low-grade inflammation
- Elevates triglycerides and contributes to unfavorable lipid patterns
- Increases risk for non-alcoholic fatty liver disease
- Increases long-term risk for type 2 diabetes and cardiovascular disease
One of the most important things to understand about insulin resistance in PMOS is that it is not exclusive to women with obesity. Lean women can have significant insulin resistance and its downstream effects. Body weight alone is not a reliable indicator of metabolic status.
Fasting glucose and hemoglobin A1c (HbA1c) are useful starting points, but they may not fully capture early or moderate insulin resistance. Fasting insulin, when clinically appropriate, can add context. HOMA-IR, a calculation using fasting glucose and fasting insulin, is one way clinicians estimate insulin resistance, though no single measure is perfect.
Improving insulin sensitivity through nutrition, movement, sleep, and stress physiology is one of the most evidence-supported levers in PMOS management. Medications that target insulin resistance, including metformin and, in appropriate contexts, GLP-1 receptor agonists, may be part of a clinician-guided plan for some women.
PMOS, Perimenopause, and Menopause
One of the most under addressed aspects of PMOS is what happens to it after the reproductive years. The short answer is that it does not simply go away.
The hormonal architecture of PMOS does not dissolve with menopause. Insulin resistance persists. Androgen pathways remain active. Cardiometabolic risk does not reset. In fact, for many women, midlife becomes the period where PMOS-related physiology becomes most clinically significant, because the protective effects of estrogen are no longer present.
Women who were never diagnosed but who have PMOS-related physiology may receive their first workup in midlife when metabolic markers worsen or symptoms become more difficult to attribute to other causes.
Key considerations for midlife women with PMOS or suspected PMOS:
Cycle irregularity becomes harder to read. In perimenopause, irregular cycles are expected. In PMOS, they were already present. The overlap makes it easy for clinicians to attribute everything to perimenopause and stop investigating further. Women deserve a more thorough evaluation.
Androgen symptoms may not improve with age. Some women with PMOS notice their androgen-related symptoms, such as facial hair or scalp thinning, worsen rather than improve in perimenopause, as the estrogen-androgen ratio shifts.
Cardiometabolic monitoring becomes more important. Women with PMOS have higher rates of hypertension, dyslipidemia, insulin resistance, and type 2 diabetes compared to women without the condition. These risks do not disappear at menopause. They compound with aging-related cardiovascular changes. Proactive monitoring matters.
Hormone therapy deserves an individualized conversation. For women navigating perimenopause or menopause who also have PMOS, hormone therapy may be appropriate for some women in some contexts. This is a clinical decision that requires individual evaluation, not a universal recommendation in either direction.
Women with PMOS should not age out of care. The reproductive window closing does not mean the conversation ends.
What Labs and Markers May Help Build a Clearer Picture
Testing should always be individualized. Not every woman needs every marker on this list. A clinician should determine which assessments are appropriate based on your history, symptoms, cycle status, family history, and clinical presentation.
That said, the following labs are commonly discussed in the context of PMOS evaluation and ongoing monitoring:
Glucose and Insulin Metabolism
- Fasting glucose
- Fasting insulin, when clinically appropriate
- Hemoglobin A1c (HbA1c)
- HOMA-IR calculation, when fasting glucose and insulin are both measured
Lipids and Cardiovascular Markers
- Fasting lipid panel, including total cholesterol, LDL, HDL, and triglycerides
- High-sensitivity C-reactive protein (hs-CRP), when appropriate for inflammatory context
Liver
- Liver enzymes, including ALT and AST, given elevated risk for non-alcoholic fatty liver disease
Thyroid
- TSH and thyroid markers when clinically indicated, particularly to exclude thyroid dysfunction as a contributing cause
Androgen and Reproductive Hormones
- Total testosterone
- Free testosterone or free androgen index
- Sex hormone-binding globulin (SHBG)
- DHEA-S
- LH and FSH, when clinically appropriate based on cycle status and diagnostic questions
- Estradiol and progesterone, based on cycle status and symptoms
- AMH, in adult women when appropriate for ovarian assessment
Nutritional and General
- Vitamin D, given common insufficiency and its relationship to insulin sensitivity and immune function
Physical and Body Composition
- Blood pressure
- Waist circumference or body composition assessment using validated methods
Again, this is not a universal testing prescription. It is a framework for conversation with your clinician.
Treatment: Why PMOS Requires a Personalized Plan
There is no single protocol for PMOS. There is no one diet, one medication, one supplement, or one approach that works for every woman. Anyone telling you otherwise is oversimplifying a complex condition.
What works is an individualized plan built around understanding your specific pattern of PMOS, your labs, your symptoms, your life stage, your goals, and your history. Here is what evidence-informed care for PMOS typically draws from:
Nutrition Nutrition has a meaningful impact on insulin sensitivity, androgen levels, inflammation, and weight in PMOS. Emphasis on adequate protein, fiber-rich carbohydrates, healthy fats, and consistent meal timing is generally well-supported. What is not supported is a one-size-fits-all dietary prescription. Low-glycemic, Mediterranean-style, and whole-food-based approaches have evidence behind them, but individual needs vary considerably.
Strength Training Resistance training improves insulin sensitivity, supports body composition, preserves lean muscle mass, and has metabolic benefits that extend well beyond aesthetics. For women with PMOS, particularly in midlife when muscle mass begins to decline, strength training is one of the most important lifestyle interventions available.
Walking and Zone 2 Cardio Lower-intensity steady-state cardiovascular activity, including brisk walking, improves mitochondrial function, reduces visceral fat, lowers fasting insulin, and is accessible for most women at most fitness levels.
Sleep Inadequate or disrupted sleep worsens insulin resistance, increases cortisol, disrupts appetite hormones, and raises inflammatory markers. For women with PMOS, addressing sleep quality is not optional. It is clinical.
Stress Physiology Chronic stress elevates cortisol, which impairs insulin sensitivity, promotes visceral fat storage, and dysregulates the hypothalamic-pituitary-adrenal axis. Stress reduction is a physiological intervention, not a soft suggestion.
Cycle and Reproductive Support For women who want cycle regulation, ovulation induction, or fertility support, there are established pharmacological and supportive options. These are clinical decisions made in context, not universal starting points.
Androgen Symptom Management For hirsutism, acne, and scalp hair thinning, options may include hormonal therapies, anti-androgen medications, and dermatologic approaches, tailored to the individual.
Metabolic Medications Metformin has the longest track record in PMOS. GLP-1 receptor agonists are increasingly discussed in the context of insulin resistance, weight management, and cardiometabolic risk in PMOS, and may be appropriate for some women in some clinical contexts. These are not universal prescriptions. They are tools in a larger plan.
Hormone Therapy in Perimenopause or Menopause For women with PMOS navigating perimenopause or menopause, hormone therapy may be appropriate in some cases to address symptom burden, bone density, cardiovascular risk, and metabolic support. This is an individualized clinical decision.
Supplements as Supportive, Not Primary Inositols, particularly myo-inositol and D-chiro-inositol, berberine, magnesium, vitamin D, and omega-3 fatty acids have varying levels of evidence for supportive roles in PMOS. They are not replacements for foundational lifestyle changes or medical care. They can be part of a thoughtfully designed plan.
Ongoing Monitoring PMOS is a lifelong condition. Care should include regular reassessment of metabolic markers, hormone levels, symptoms, and overall health trajectory. It is not a diagnose-and-discharge situation.
How 1st Optimal Looks at PMOS Differently
At 1st Optimal, we work with high-achieving women who have often been told their labs are “normal” while they feel anything but. They are tired, they are frustrated, and they are ready for a more thorough explanation of what is actually happening in their bodies.
Our approach to PMOS is lab-informed, medically guided, and built around the individual.
That means we start with comprehensive testing. We look at glucose and insulin metabolism, not just fasting glucose in isolation. We look at androgens with enough specificity to understand how they are being produced and how much is biologically active. We look at thyroid function, inflammation, lipids, liver markers, body composition, and reproductive hormones appropriate to your cycle status and age.
We interpret results in clinical context, not against population reference ranges that were never designed to define optimal health for a high-achieving woman in her 40s.
And we build a plan that reflects your actual physiology, not a protocol template. For some women, that means targeted nutrition guidance and a structured strength training program. For others, it means working through androgen symptom management, metabolic medications, or hormone therapy conversations. For many, it means all of the above, sequenced thoughtfully.
We also address the psychological dimension of PMOS, because the years of feeling dismissed, misdiagnosed, or told that symptoms were “just stress” or “just aging” have an impact on how women engage with their health care. We take that seriously.
If you have ever left a clinical appointment feeling like your concerns were minimized, or been handed a prescription without a conversation, we want to offer something different.
Book a free consult to learn whether deeper hormone and metabolic testing is the right next step for you.
What This Name Change Means Going Forward
Terminology shapes clinical conversations. It shapes what gets measured, what gets addressed, what gets researched, and what women are told about their own health.
The shift from PCOS to PMOS is more than semantic. When a condition is named after follicles on an ovary, clinicians are oriented toward that finding. When a condition is named for the multi-system endocrine and metabolic reality it represents, the entire clinical orientation expands.
Better terminology can improve awareness among clinicians who never received adequate training on the metabolic dimensions of this condition. Better awareness can improve the rate and accuracy of diagnosis across diverse presentations and body types and life stages. Better diagnosis can lead to earlier intervention, more comprehensive monitoring, and more complete care.
Research will continue to refine the diagnostic criteria and management evidence base. The 2028 International Guideline update will formalize the next stage of this work. In the meantime, women and their clinicians can use the new name as an invitation to look at the condition through a wider lens.
The name PMOS does not solve every gap in women’s health care. But it tells a more accurate story. And in medicine, accurate stories lead to better questions, better evaluation, and better outcomes.
FAQ:
Is PCOS now called PMOS? Yes. Polycystic Ovary Syndrome has been officially renamed Polyendocrine Metabolic Ovarian Syndrome, or PMOS. The announcement was made on May 12, 2026, published in The Lancet, and presented at the European Congress of Endocrinology. The transition is underway, with full implementation expected in the 2028 International Guideline update.
What does PMOS stand for? PMOS stands for Polyendocrine Metabolic Ovarian Syndrome. Each word reflects a key dimension of the condition: multiple hormone systems are involved (polyendocrine), metabolic dysfunction such as insulin resistance is a core feature (metabolic), and ovarian function still plays an important role (ovarian).
Why was PCOS renamed? The old name was clinically misleading. “Polycystic” suggested that ovarian cysts were central to the condition, but the structures seen on ultrasound are typically follicles, not abnormal cysts. Many women with the condition have no polycystic ovarian appearance. The name over-focused on ovaries and fertility, contributing to missed diagnoses, stigma, and incomplete care.
Are ovarian cysts required for PMOS? No. Ovarian cysts are not required for diagnosis. The structures sometimes seen on ultrasound in PMOS are typically small follicles in greater-than-typical numbers, not abnormal cysts. Some women with PMOS have no polycystic ovarian morphology at all.
Is PMOS only a fertility condition? No. While ovulatory dysfunction and fertility implications are part of the clinical picture for some women, PMOS is a whole-body hormonal and metabolic condition. Its features span insulin resistance, cardiovascular risk, androgen-related symptoms, psychological health, sleep, and long-term metabolic disease risk. Fertility is one dimension, not the defining one.
Can PMOS affect women in perimenopause? Yes, significantly. PMOS does not resolve at perimenopause. In many women, the metabolic dimensions of the condition become more prominent as estrogen declines. Cycle irregularity, androgen symptoms, visceral fat accumulation, insulin resistance, and cardiovascular risk can all be amplified by the hormonal shifts of perimenopause.
Does PMOS increase metabolic risk? Yes. Women with PMOS have elevated risk for insulin resistance, type 2 diabetes, dyslipidemia, non-alcoholic fatty liver disease, hypertension, and cardiovascular disease compared to women without the condition. This risk increases further with age and with the estrogen decline of menopause.
Does the name change affect my diagnosis? Not immediately. Diagnostic criteria are still based on the 2023 International Evidence-Based Guideline while the terminology transition occurs. Full implementation of any updated framework is expected with the 2028 guideline update. If you have an existing PCOS diagnosis, that diagnosis remains valid. If you are pursuing a new diagnosis, your clinician should still be applying current international criteria.
What labs should women with PMOS discuss with their clinician? A comprehensive evaluation may include fasting glucose, fasting insulin, hemoglobin A1c, a lipid panel, liver enzymes, thyroid markers when indicated, total and free testosterone, SHBG, DHEA-S, AMH in adult women when appropriate, LH and FSH based on clinical context, estradiol and progesterone based on cycle status, vitamin D, hs-CRP when appropriate, blood pressure, and body composition assessment. Testing should be individualized based on your symptoms, history, and clinical picture.
Can PMOS continue after menopause? Yes. PMOS does not resolve with menopause. The metabolic, cardiovascular, and hormonal features of the condition persist beyond the reproductive years. Women with PMOS need ongoing monitoring and care that reflects the long-term nature of the condition, not care that stops when fertility is no longer a concern.
What is the best treatment for PMOS? There is no single best treatment for PMOS. The condition is heterogeneous and requires an individualized plan. Evidence-informed care typically draws from nutrition, resistance training, cardiovascular exercise, sleep optimization, stress physiology support, cycle or androgen management when appropriate, metabolic medications when indicated, and hormone therapy considerations in perimenopause or menopause. Supplements may play a supportive role. Ongoing monitoring is essential.
How does 1st Optimal approach hormone and metabolic testing? At 1st Optimal, we use advanced, comprehensive lab panels to assess hormone status, glucose and insulin metabolism, inflammatory markers, lipids, liver function, thyroid health, and body composition. We interpret results in functional context, not just against standard reference ranges. We build individualized plans based on your actual physiology, not a one-size protocol. Every woman we work with receives a personalized evaluation and a clinician-guided treatment plan. Book a free consult to learn what a deeper look at your hormone and metabolic health could reveal.
Conclusion
PMOS is not a new condition. The name is new. And the name finally tells the truth about what this condition is.
For decades, women with PCOS were reduced in clinical practice to their ovaries and their fertility. Their insulin resistance was undertreated. Their cardiovascular risk was under monitored. Their androgen symptoms were managed symptomatically without addressing root physiology. Their psychological burden was minimized. Their concerns in midlife were attributed to aging.
The renaming of PCOS to Polyendocrine Metabolic Ovarian Syndrome does not fix every one of those failures overnight. But it anchors clinical care in a more accurate framework. It signals to the research community, to guideline developers, to medical educators, and to clinicians that this condition is more than its former name implied.
Women with PMOS deserve care that sees the endocrine picture, the metabolic picture, the reproductive picture, the psychological picture, and the long-term cardiovascular picture, all at once, from adolescence through midlife and beyond.
A better name should lead to better conversations. Better conversations should lead to better testing. Better testing should lead to better care.
You are not your ovaries. You are not your fertility status. You are not your weight. You are not a single lab value. You are a whole-body system, and you deserve care that treats you that way.
Ready to understand what your hormones and metabolic markers are actually telling you? Book a free 1st Optimal consult today.
References:
- Endocrine Society PMOS name change announcement
- The Lancet PMOS naming article
- 2023 International Evidence-Based Guideline for PCOS
- ASRM 2023 PCOS guideline summary
- Monash PCOS guideline summary
